GMR CAR-T / Shinshu University - LARVOL DELTA

Current status and future perspective of CAR T-cell therapy for acute myeloid leukemia (PubMed, Rinsho Ketsueki) - "We started a first-in-human clinical trial of GMR CAR T-cells in patients with CD116-positive myeloid neoplasms, particularly AML and juvenile myelomonocytic leukemia, in 2021. CAR T-cells can be a promising and practical treatment option for patients with relapsed/refractory AML."

CAR T-Cell Therapy • Journal • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Juvenile Myelomonocytic Leukemia • Leukemia • Oncology • CD123 • CD33 • NKG2D

A first-in-human clinical trial of piggyBac transposon-mediated GMR CAR-T cells against CD116-positive acute myeloid leukemia and juvenile myelomonocytic leukemia (PubMed, Rinsho Ketsueki) - "Safety tests revealed that the toxicity of GMR CAR-T cells was restricted to normal monocytes. Based on the promising results of the nonclinical study, we started a first-in-human clinical trial of GMR CAR-T cells in patients with CD116-positive AML and JMML in 2021."

CAR T-Cell Therapy • IO biomarker • Journal • P1 data • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Juvenile Myelomonocytic Leukemia • Leukemia • Oncology • CSF2

A first-in-human clinical trial of GMR CAR-T for CD116 + myeloid malignancies (JSTCT 2022) - No abstract available

Clinical • P1 data • Hematological Malignancies • Oncology

A Phase I/II Clinical Trial of Piggybac -Modified GMR CAR-T Cell Therapy for CD116 Positive Relapsed/Refractory Myeloid Malignancies (ASH 2021) - "The patient will be treated with lymphodepleting chemotherapy consisting of fludarabine and cyclophosphamide, followed by CAR-T cell infusion. Conclusion : We herein described the protocol of first-in-human GMR CAR-T cells for relapsed/refractory myeloid malignancies. By employing the optimized CAR vector and production protocol, the safety and efficacy of GMR CAR-T cells will be evaluated in this study."

CAR T-Cell Therapy • Clinical • IO biomarker • P1/2 data • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Chronic Myelomonocytic Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Juvenile Myelomonocytic Leukemia • Leukemia • Oncology • Transplantation • CSF2